SciBase Holding AB, a leading developer of augmented intelligence-based solutions for skin disorders announced that it has on-boarded several US dermatology practices that specialize in skin cancer detection, diagnosis and treatment. Through these US practices, SciBase will further their mission to improve outcomes for patients and clinicians by expanding access of the Nevisense test to additional states in the US.
“The innovative Nevisense test provides us the point-of-care capability in diagnosing melanoma at the earliest possible stage. This is extremely important for our patients because early-stage melanoma is almost 100% curable. Given that melanoma is the deadliest form of skin cancer with about 20 people dying of the disease per day in the US, early detection becomes critical to survival,” said Dr. Michael McPhee, surgical oncologists, owner and managing director of the Melanoma Clinic in Orlando, Florida.
Health Technology Insights: 49 HCA Healthcare Hospitals Recognized as “America’s Best Hospitals” by Healthgrades
“To date, evaluating atypical moles at point-of-care to assess and guide biopsy decisions remains challenging, even for experienced dermoscopists. Early melanomas and even some invasive melanomas can have very few morphologic features, which make it challenging to assess at point-of-care. The Nevisense tests is non-invasive and provides us with important cellular data from below the skin surface before we make our biopsy decision, enabling improved atypical mole management for our patients,” said Dr. Alison Z. Young, dermatologist and dermatopathologist, and owner of Young Dermatology in Seattle, Washington.
Health Technology Insights: NLS Pharmaceutics Announces the Submission of Three Research Abstracts 2025 ASCP Annual Meeting
“SciBase is dedicated to its mission of empowering healthcare professionals to improve diagnostic accuracy, enable disease monitoring, and facilitate early intervention of skin cancer and skin disorders. We are pleased to be able to give our full support to clinicians like Dr. McPhee and Dr. Young who are deeply committed and focused on skin cancer patients,” said Pia Renaudin, CEO of SciBase.
Health Technology Insights: Siolta Therapeutics and Cowellnex Enter Joint Research Agreement
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
